Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: Results of a randomized, double-blind, placebo-controlled study

Journal of Clinical Psychiatry

Volumn 69, Issue 11, 2008, Pages 1766-1775

  Spencer, Thomas J ^a   Landgraf, Jeanne M ^b   Adler, Lenard A ^c   Weisler, Richard H ^d,e   Anderson, Colleen S ^f   Youcha, Sharon H ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HealthActCHQ   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f SHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; APLENZIN; ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE; PLACEBO; SPD 465; UNCLASSIFIED DRUG;

ADULT; ADULT ATTENTION DEFICIT HYPERACTIVITY DISORDER IMPACT MODULE; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA;

EID: 57349164002     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n1112     Document Type: Article

References (26)

1. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-723
2. Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 2006;67(4):524-540
3. Adler LA. Clinical presentations of adult patients with ADHD. J Clin Psychiatry 2004;65(suppl 3):8-11
4. Able SL, Johnston JA, Adler LA, et al. Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med 2007;37:97-107
5. Adler LA, Sutton VK, Moore RJ, et al. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol 2006;26:648-652
6. de Graaf R, Kessler RC, Fayyad J, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative [published online ahead of print May 27, 2008]. Occup Environ Med
7. Sawyer MG, Whaites L, Rey JM, et al. Health-related quality of life of children and adolescents with mental disorders. J Am Acad Child Adolesc Psychiatry 2002;41:530-537
8. Goodman DW, Ginsberg L, Weisler RH, et al. An interim analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QUEST) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 2005;10:26-34
9. Perwien AR, Kratochvil CJ, Faries DE, et al. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes? J Child Adolesc Psychopharmacol 2006;16:713-724
10. Landgraf JM. ADHD-specific quality of life with mixed amphetamine salts extended release in adults with ADHD. Presented at the 159th annual meeting of the American Psychiatric Association; May 24, 2006; Toronto, Ontario, Canada
11. Landgraf JM. Monitoring quality of life in adults with ADHD: reliability and validity of a new measure. J Atten Disord 2007;11:351-362
12. Prasad S, Harpin V, Poole L, et al. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin 2007;23:379-394
13. Matza LS, Johnston JA, Faries DE, et al. Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL). Qual Life Res 2007;16(9):1511-1520
14. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41:26S-49S
15. Goksoyr PK, Nottestad JA. The burden of untreated ADHD among adults: the role of stimulant medication. Addict Behav 2008;33:342-346
16. Landgraf JM, Arnold LE, McKay MJ. Treatment satisfaction after conversion from oral methylphenidate to transdermal methylphenidate. Presented at the 160th annual meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, Calif
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000
18. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:187-201
19. Center for Drug Evaluation and Research. Guidance for Industry, E6 Good Clinical Practice: Consolidated Guidance. Rockville, Md: Center for Drug Evaluation and Research; 1996
20. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV. New York, NY: Guilford Press; 1998
21. Guy W. Clinical Global Impression (CGI). ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health, Psychopharmacology Research Branch; 1976:218-222
22. Brown TE. Brown Attention-Deficit Hyperactivity Disorder Scales for Adolescents and Adults. Toronto, Ontario, Canada: The Psychological Corporation, Harcourt Assessment Canada; 1996
23. Adler LA, Sitt D, Faraone S, et al. Reliability and validity of the Time-Sensitive ADHD Symptom Scale (TASS) in adults. Presented at the 53rd annual meeting of the American Academy of Child and Adolescent Psychiatry; Oct 27, 2006; San Diego, Calif
24. Spencer TJ, Adler LA, Weisler RH, et al. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced, extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry 2008;69(9):1437-1448
25. Brown TE, Spencer TJ, Youcha SH, et al. Improved executive functions with triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation, in adults with ADHD [poster]. Presented at the 47th annual New Clinical Drug Evaluation Unit; June 12, 2007; Boca Raton, Fla
26. Brod M, Johnston J, Able S, et al. Validation of the Adult Attention-deficit/Hyperactivity Disorder Quality-of-Life Scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res 2006;15:117-129